Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALDX |
---|---|---|
09:32 ET | 10147 | 4.05 |
09:34 ET | 300 | 4.05 |
09:36 ET | 400 | 4.1 |
09:38 ET | 2721 | 4.0989 |
09:41 ET | 5225 | 4.07 |
09:45 ET | 100 | 4.09 |
09:50 ET | 850 | 4.095 |
09:52 ET | 556 | 4.0715 |
09:54 ET | 615 | 4.12 |
09:56 ET | 100 | 4.12 |
09:59 ET | 100 | 4.11 |
10:01 ET | 100 | 4.08 |
10:03 ET | 100 | 4.07 |
10:08 ET | 3987 | 4.0799 |
10:14 ET | 3600 | 4.08 |
10:15 ET | 200 | 4.07 |
10:17 ET | 1362 | 4.0615 |
10:19 ET | 2555 | 4.08 |
10:21 ET | 1100 | 4.08 |
10:24 ET | 200 | 4.095 |
10:26 ET | 1026 | 4.11 |
10:32 ET | 2433 | 4.128 |
10:37 ET | 200 | 4.14 |
10:39 ET | 265 | 4.16 |
10:42 ET | 250 | 4.15 |
10:44 ET | 100 | 4.17 |
10:48 ET | 200 | 4.17 |
10:51 ET | 2398 | 4.16 |
10:53 ET | 4129 | 4.17 |
10:55 ET | 100 | 4.17 |
11:00 ET | 300 | 4.19 |
11:02 ET | 1735 | 4.19 |
11:04 ET | 855 | 4.17 |
11:06 ET | 300 | 4.1608 |
11:09 ET | 600 | 4.14 |
11:11 ET | 800 | 4.1301 |
11:13 ET | 600 | 4.14 |
11:24 ET | 1135 | 4.16 |
11:26 ET | 383 | 4.17 |
11:29 ET | 307 | 4.17 |
11:33 ET | 1600 | 4.175 |
11:36 ET | 100 | 4.175 |
11:38 ET | 100 | 4.175 |
11:42 ET | 500 | 4.165 |
11:44 ET | 6174 | 4.17 |
11:45 ET | 646 | 4.16 |
11:54 ET | 100 | 4.19 |
11:56 ET | 300 | 4.188 |
11:58 ET | 2485 | 4.17 |
12:05 ET | 100 | 4.18 |
12:14 ET | 100 | 4.18 |
12:16 ET | 12675 | 4.2 |
12:18 ET | 100 | 4.205 |
12:20 ET | 100 | 4.22 |
12:23 ET | 1700 | 4.22 |
12:25 ET | 200 | 4.205 |
12:30 ET | 200 | 4.22 |
12:32 ET | 1600 | 4.21 |
12:34 ET | 200 | 4.21 |
12:36 ET | 400 | 4.22 |
12:41 ET | 100 | 4.21 |
12:43 ET | 2356 | 4.2224 |
12:48 ET | 100 | 4.24 |
12:50 ET | 2600 | 4.215 |
12:56 ET | 654 | 4.22 |
01:01 ET | 233 | 4.21 |
01:03 ET | 100 | 4.21 |
01:12 ET | 100 | 4.22 |
01:17 ET | 2600 | 4.207 |
01:19 ET | 118 | 4.21 |
01:30 ET | 100 | 4.21 |
01:32 ET | 100 | 4.22 |
01:33 ET | 100 | 4.21 |
01:35 ET | 1197 | 4.2 |
01:37 ET | 100 | 4.2 |
01:39 ET | 145 | 4.1923 |
01:42 ET | 2764 | 4.21 |
01:44 ET | 896 | 4.2015 |
01:46 ET | 200 | 4.2 |
01:55 ET | 491 | 4.1918 |
02:00 ET | 867 | 4.185 |
02:02 ET | 2207 | 4.1858 |
02:06 ET | 100 | 4.185 |
02:09 ET | 580 | 4.185 |
02:11 ET | 200 | 4.19 |
02:15 ET | 1100 | 4.19 |
02:20 ET | 100 | 4.2 |
02:22 ET | 800 | 4.2 |
02:24 ET | 100 | 4.205 |
02:27 ET | 200 | 4.2 |
02:29 ET | 2864 | 4.2 |
02:33 ET | 1000 | 4.2093 |
02:36 ET | 1053 | 4.1989 |
02:38 ET | 200 | 4.2 |
02:40 ET | 200 | 4.19 |
02:42 ET | 100 | 4.1864 |
02:44 ET | 250 | 4.185 |
02:45 ET | 950 | 4.185 |
02:47 ET | 145 | 4.19 |
02:49 ET | 100 | 4.185 |
02:51 ET | 300 | 4.19 |
02:54 ET | 100 | 4.1953 |
02:56 ET | 200 | 4.195 |
02:58 ET | 1911 | 4.17 |
03:00 ET | 100 | 4.17 |
03:03 ET | 900 | 4.17 |
03:07 ET | 903 | 4.16 |
03:12 ET | 800 | 4.16 |
03:16 ET | 100 | 4.16 |
03:20 ET | 100 | 4.1572 |
03:21 ET | 100 | 4.16 |
03:25 ET | 885 | 4.14 |
03:30 ET | 200 | 4.15 |
03:32 ET | 3006 | 4.135 |
03:34 ET | 450 | 4.14 |
03:36 ET | 100 | 4.135 |
03:39 ET | 2640 | 4.14 |
03:41 ET | 100 | 4.14 |
03:43 ET | 2076 | 4.155 |
03:45 ET | 1125 | 4.1618 |
03:50 ET | 100 | 4.16 |
03:52 ET | 100 | 4.16 |
03:54 ET | 3879 | 4.18 |
03:56 ET | 902 | 4.18 |
03:57 ET | 2057 | 4.17 |
03:59 ET | 4072 | 4.18 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aldeyra Therapeutics Inc | 229.3M | -8.2x | --- |
Design Therapeutics Inc | 228.8M | -4.0x | --- |
Eliem Therapeutics Inc | 224.3M | -16.3x | --- |
Opthea Ltd | 224.2M | -1.0x | --- |
XBiotech Inc | 220.8M | -7.1x | --- |
Acrivon Therapeutics Inc | 238.4M | -2.6x | --- |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.